BC Platforms serves as medium for MS research
Finnish BC Platforms offers its technology solutions and research platform to Biogen and the Accelerated Cure Project (ACP) to advance research into multiple sclerosis (MS).
BC Platforms‘ offering includes the recently launched BC|RQUEST, which enables Biogen and ACP to analyse combined genomic and clinical data and organise effective collaboration between biobanks and MS researchers.
US tech giant Microsoft will also participate by providing the necessary cloud platform for indexing and accessing the information globally.
“MS affects at least 2.3 million people worldwide,” says Robert McBurney, CEO of ACP. “BC Platforms’ technology provides an efficient way to manage the growth of our data repository, increases its visibility to the research community, and offers a simple way for researchers to collaborate and test hypotheses, especially those involving genetic data.”
The patient-founded ACP is a non-profit organisation directly involved with research efforts to improve diagnosis, optimise treatment and advance cures for MS. Itse data repository on the disease will now be made available to researchers around the world through BC|RQUEST.
Biogen, ACP and Microsoft are all part of the Open Biobank Research Enhancement Alliance (OBREA), a BC Platforms initiative that connect biobanks, technology enablers, researchers and industry.
BC Platforms has also announced a collaboration with the UK Clinical Research Collaboration Tissue Directory and Coordination Centre (UKCRC TDCC). Their aim is to explore the development of a unique research platform, which also uses BC|RQUEST, for more than 150 biobanks in the UK.
BC Platforms envisions becoming the world’s leading analytics resource for healthcare and industry by 2020.